ADCT announced that it will host a conference call and live webcast on November 8, 2022 to report financial results for the third quarter.
Immunogen announced findings from a retrospective pooled analysis of patients who achieved extended treatment benefit (ETB) with mirvetuximab soravtansine monotherapy across three clinical trials in FRα–positive recurrent ovarian cancer. These findings were highlighted in a poster presentation at the 23rd Congress of ESGO in Berlin.
Mersana announced the completion of patient enrollment in UPLIFT trial of UpRi in platinum-resistant ovarian cancer. UpRi is Mersana’s first-in-class NaPi2b-targeting ADC with a novel scaffold-linker-payload.
Seagen came out with a quarterly loss of $191 million, or $1.03 per share versus the estimate of a loss of $0.92. This compares to loss of $1.61 per share a year ago.
The short interest of Alkermes increased in October by 4% to 9,088,530 on October 14, compared to 8,734,973 on September 15.
ImmunityBio announced it will be presenting at the Jefferies London Healthcare Conference, which is taking place in London from November 15-17, 2022.
Nektar will announce its financial results for the third quarter 2022 on Thursday, November 3, 2022.
Xencor announced seven poster presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer in Boston. Data from the first patients enrolled in a Phase 2 study of vudalimab, Xencor’s selective PD-1 x CTLA-4 bispecific antibody, plus chemotherapy in patients with mCRPC, will be presented in abstract 668.
Allogene announced the initiation of the potentially pivotal Phase 2 trial of ALLO-501A (ALPHA2 trial) in patients with relapsed/refractory large B-cell lymphoma. The company is also in process of initiating the EXPAND trial, which is intended to demonstrate the contribution of ALLO-647 to the standard fludarabine/ cyclophosphamide lymphodepletion regimen. Assuming favorable outcomes and subject to discussions with FDA, the company expects these studies to support the regulatory approval of ALLO-501A and ALLO-647.
Autolus entered into agreement with BMS, which grants the big pharma access to incorporate Autolus’ proprietary RQR8 safety switch into an initial set of selected cell therapy programs on a target-by-target basis for the treatment of cancer, with an option for BMS to incorporate the RQR8 safety switch in additional cell therapy programs beyond the initial set of selected programs. Separately, Moderna has exercised its option to license Autolus’ proprietary binders against an undisclosed immuno-oncology target for the development and commercialization of mRNA therapeutics. No financial details were disclosed.
Bellicum participated at the annual Cell & Gene Meeting on the Mesa. The short interest of Bellicum increased in October by 105% to 132,932 on October 14, compared to 64,967 on September 15.
Mustang announced that results from the Waldenstrom macroglobulinemia (WM) cohort and other interim data from the ongoing Phase 1/2 trial of MB-106, a CD20-targeted, autologous CAR T cell therapy were presented at the 11th International Workshop for Waldenstrom's Macroglobulinemia in Madrid. ORR of 96% and CR rate of 75% was observed in a wide range of hematologic malignancies including follicular lymphoma, CLL, and DLBCL; a 100% ORR and CR was observed in the two patients with WM.
Immutep announced that FDA granted Fast Track designation to its IMP321 in combination with pembrolizumab for the treatment of 1st line NSCLC. Separately, Immutep announced the Independent Data Monitoring Committee for the randomized, controlled Phase 2b TACTI-003 trial has reviewed initial safety data and recommended continuing the trial with no modifications.
Clovis announced positive top-line data from Phase 3 TRITON3 demonstrating Rubraca monotherapy treatment achieved the primary endpoint of significantly improved rPFS by IRR compared with the control group, which consisted of physician’s choice of docetaxel, abiraterone acetate, or enzalutamide. Median rPFS of 11.2 months for Rubraca vs 6.4 months for control group in BRCA subgroup. Median rPFS of 10.2 months for Rubraca vs 6.4 months for control group in ITT population.